Regeneron, Bayer Report Positive Results from Phase 3 Trials of EYLEA Injection for Treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Bayer HealthCare (OTC: BAYRY ) today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly and EYLEA 2 mg dosed every two